Drexel Logo


Karen Rose 
ASH - Delaware Valley 


Wednesday October 10, 2012 from 8:30 AM to 12:30 PM EDT

Add to my calendar 


Drexel Univserity College of Medicine 
Philadelphia, PA 19102 



Allan B. Schwartz, M.D.
Vice President, ASH Delaware Valley Chapter
Professor of Medicine
Division of Nephrology and Hypertension
Department of Medicine
Drexel University College of Medicine
Philadelphia, PA.

Christopher McFadden, M.D.
President, ASH Delaware Valley Chapter
Assistant Professor of Medicine
Program Director, Nephrology Fellowship
Cooper Medical School of Rowan University,
Camden, N.J.


  • recognize hypertension management recent advances
  • discuss JNC 8 newest recommendations: Targets and Goals; Evidence, Co-Morbidities; JNC 8 process for new hypertension guidelines
  • review Anti-RAAS therapy, combinations: Pros and Cons
  • recognize Potassium Balance changes in Hypertension
  • recognize and manage resistant hypertension
  • discuss new advances with implantable electronic devices
  • plan treatment of hypertension in chronic kidney disease


  • Hypertension management recent advances
  • JNC 8 Process and  Recommendations:
  • Blood Pressure Targets and Goals;
  • Recent Evidence of Co-Morbidities;
  • Dual-RAAS Blockade: Pros and Cons
  • Potassium Balance in Hypertension
  • Adrenal Gland  hypertension & metabolic abnormalities
  • Resistant Hypertension and Role of Sympathetic Nervous System
  • New  Implantable Electronic Devices to Control Hypertension
  • Treatment of Hypertension in Chronic Kidney Disease     

Additional support from the
Delaware Academy of Medicine

DAM logo


Hypertension Highlights - ASH 2012 


The “Hypertension HighLights-ASH 2012” program is designed to provide clinicians with the most up to date strategies and therapeutic goals for the prevention, diagnosis and control of hypertension and cardiovascular co-morbidities. HighLights of the American Society of Hypertension 2012 meeting will be emphasized.

This program will feature updated recommendations for management of hypertension including: Projections of the Joint National Committee 8 (JNC8): What is "Hypertension?" Which Number, At What Age and When to Treat; Critical look at Existing BP Goals and the Supporting Evidence; Treatment Targets in co-morbidities such as CKD and Diabetes; Review Antihypertensive Medicine Classes: Diuretics, Calcium Channel Blockers, Beta Blockers, ACE Inhibitors, ARBs, etc., Benefits & Risks. Dual Blockade of Renin Angiotensin Aldosterone (Anti-RAAS) drug therapy and new  data on benefits and risks including  Pro and Con Debate. Additional Topics will include Potassium balance abnormalities in Hypertension, Resistant Hypertension, recognition and management, New SNS Intervention Implantable Devices, Chronic Kidney Disease with Hypertension.

Young Investigator Hypertension Abstracts will be recognized.

Q and A sessions, Panel Discussion, Audience Participation will be encouraged


8:30 AM  - 12:30 PM Seminar
12:30 P.M. – 2:00 P.M. Education and Business Meeting

7:30 A.M.    Registration and Continental Breakfast, Geary B. Lobby

8:30 .AM.    Introduction: Advances in Hypertension Management
Allan B. Schwartz, M.D.

8:40 A.M.    New Hypertension Guidelines -  A Review of the JNC 8 Recommendations: Treatment Targets and Goals; Supporting Evidence; Co-Morbidities: Diabetes, CKD, CAD, CVA 
Raymond Townsend, M.D.

9:20 A.M. Dual Anti-Renin Angiotensin Aldosterone (Anti-RAAS) drug therapy and new data indicating benefits and risks of dual therapy. Presenters will debate Pros and Cons.

PRO…Christopher McFadden, M.D.
CON…Alan H. Gradman, M.D.

10:30 A.M. Potassium Balance in Hypertension
Allan B. Schwartz, M.D.

11:00 A.M.  Sympathetic Nervous System, Resistant Hypertension,  and Implantable Interventional Devices
Debbie Cohen, M.D.

11:30 A.M.    Panel Discussion and Clinical Case Discussions
Ellie Kelepouris, M.D., Moderator

Case 1  -  Resistant Hypertension
Hasan Arif, M.D.

Case 2  -  Hypertension with Chronic Kidney Disease
 Ami Patel, M.D.

12:10 P.M.    Discussion and ASH DV Hypertension Abstract Award Recognition for Young Investigators and Hypertension Trainees
Christopher McFadden, M.D., President ASH DV Chapter

12:30 P.M.     LUNCH: ASH-Delaware Valley Chapter Organizational and Educational Meeting

1:00 P.M.       Applying new Methods and Techniques in your Clinic/Community

2:00 P.M.       Adjourn

Seminar Faculty

Hasan Arif, M.D.
Instructor in Medicine
Division of Nephrology and Hypertension
Drexel University College of Medicine
Philadelphia, PA

Ellie Kelepouris, M. D.
Professor, Department of Medicine
Chief, Division of Nephrology and Hypertension
Director, Nephrology Training Program
Drexel University College of Medicine
Philadelphia, PA.

Debbie Cohen, MD
Associate Professor of Medicine
Director of Clinical Hypertension Programs
Co-Director of Penn Neuroendocrine Tumor Program Office
University of Pennsylvania School of Medicine
Philadelphia, PA.

Ami Patel, M.D.
Assistant Professor of Medicine
Division of Nephrology and Hypertension
Drexel University College of Medicine
Philadelphia, PA.

Alan H Gradman, M.D.
Immediate Past President, ASH Delaware Valley Chapter
Professor of Medicine
Temple University School of Medicine (Clinical Campus)
Pittsburgh, PA

Raymond Townsend, M.D.
Professor of Medicine
Director, Hypertension Program
University of Pennsylvania School of Medicine
Philadelphia, PA.

ACCREDITATION STATEMENT: Drexel University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement: The Drexel University College of Medicine designates this live activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AOA: This program is eligible for 5 credits in Category 2A of the American Osteopathic Association.

AAFP: Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

FACULTY DISCLOSURE STATEMENT: It is the policy of Drexel University College of Medicine to insure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. Speakers at continuing medical education activities are required to disclose to the audience their financial relationships with the manufacturer(s) of any commercial products, goods or services related to the subject matter of the program topic. Any conflicts of interest must be resolved prior to the presentation and announced to the audience. The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity and determine whether the speaker’s commercial interests influenced the presentation. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.